According to diabetes news, the new diabetes drug Onglyza will cost the same amount as Januvia, the market-leading drug created by Merck. The pricing will plunge the two drugs into direct competition.
Onglyza, made by AstraZeneca and Bristol-Myers Squibb, serves to increase the ability of the body to lower high blood sugar levels. The drug is part of a class of diabetes drugs called DPP-4 inhibitors.
People with diabetes need to maintain average blood glucose levels to lower the risk of complications . Januvia, experts say, will continue to dominate the DPP-4 market. Onglyza was recently approved by the Food and Drug Administration, the most important stage in bringing new diabetes treatments to market.
New diabetes drug same price
Thu, 06 Aug 2009
Recommended links
Diabetes symptomsOnline diabetes support
Diabetes directory
Diabetes donate
Diet plate for diabetics
Diabetes drug cleared of cancer risk
Dementia drug risk amongst people with diabetes
Iron binding drug could help diabetes neuropathy
Diabetes drug cleared of cancer risk
Canada reviews diabetes drug
Diabetes drug review causes share climb
Sanofi maintain diabetes drug no riskier than insulin
Diabetes drug cleared for European market
Drug association encourages use of diabetes drug
Diabetes drug requires more research, FDA rule
Takeda diabetes drug setback
Diabetes drug reaching stage three trials
Study confirms how diabetes drugs can increase heart risk
New diabetes drug promising results
New Glaxo diabetes drug not overwhelming
Diabetes drug found to be more effective
Diabetes drug delayed for Europe
Diabetes drug could have cancer influence
Salt influence on diabetes drugs
Diabetes amputation risk cut by cholesterol drug
Diabetes drug could cause pancreas problems
Diabetes drug fails in study
Making Third world diabetes drugs cheaper
Approval for Novo Nordisk diabetes drug
Drug could also prevent diabetes
Diabetes drug carries unknown tumour risk
Join us